Yes, there is a weight loss pill instead of injection — here's what you need to know

The misconception: injections are the only GLP-1 option

For years, the honest answer to this question was: not really. The GLP-1 medicines making headlines for weight loss were all injectable, and if you have wondered whether there is an injection for weight loss that suits you, that injectable-only landscape is what shaped most of the information you will have read. That is no longer true. On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide) as the first oral GLP-1 medicine licensed in the UK specifically for weight management. The UK was the first European country to grant that approval. So the assumption that you have to inject to access this class of treatment is now outdated.

What has not changed is that both forms are prescription-only medicines. A clinician has to review your health before either is prescribed, and that clinical assessment is there for good reason. Suitability depends on your BMI, medical history, any other medicines you take, and several other factors a prescriber is trained to weigh up. The pill does not sidestep that process — it simply removes the needle from the equation.

It is also worth being clear that "pill" here does not mean something you can pick up at a pharmacy counter. Wegovy tablets are a prescription-only medicine dispensed through a registered pharmacy following clinical approval, just like the injections. Our frequently asked questions address a number of the common queries about how this process works in practice.

What the tablet actually involves, and what the trial data showed

Wegovy tablets contain semaglutide co-formulated with an absorption enhancer called SNAC, which allows the drug to cross the stomach lining. The dosing schedule starts at 1.5 mg daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. It is taken first thing in the morning on an empty stomach with a small amount of plain water, and you wait at least 30 minutes before eating, drinking anything else, or taking other medicines. No refrigeration is needed, which matters if you travel regularly or simply find fridge storage inconvenient.

The pivotal trial (OASIS 4, a phase 3 study of 307 adults with obesity or overweight plus at least one weight-related condition, run over 64 weeks) reported an average weight loss of around 13.6% versus roughly 2.4% for placebo. Among participants who adhered fully to treatment, the average reached approximately 16 to 17%. The most common side effects were gastrointestinal: nausea, vomiting, and diarrhoea, reported in around 74% of the tablet group, typically mild to moderate and settling over time. The NHS medicines page for semaglutide covers the side effect profile in plain language.

For a fuller comparison of how the tablet sits alongside the injection options, the pill versus injection comparison sets out the key differences side by side.

Where injections still have a practical edge

The tablet's approval is significant, but injections have a longer evidence base and in some respects a less demanding daily routine. Mounjaro (tirzepatide) and the Wegovy injection are both once weekly, meaning you do not have to think about timing every morning. Mounjaro's SURMOUNT-1 trial reported average body-weight reductions of around 20 to 21% at the highest dose over 72 weeks, figures that are, so far, ahead of what the tablet has demonstrated in trials. You can read about what weight loss injections are available in the UK to understand how the injectable options compare with each other.

Injections do require a little more in the way of storage and equipment. Pens are kept refrigerated, and each injection uses a new needle. If you are curious about the practicalities, the weight loss injection guide covers technique, injection sites, and what to expect. Some people find the weekly rhythm easier to maintain than a daily tablet with the morning timing rules, others feel the opposite. That preference is a legitimate part of the conversation with a prescriber.

One practical note: if you tend to place orders around a holiday or at the end of the month when things are busy, it is worth remembering that same-day dispatch at nume requires ordering before 12 pm on a working day, useful to bear in mind when planning ahead.

Which option might suit you, and how to find out

There is no single correct answer here. The tablet suits people who want to avoid injections entirely, travel frequently, or simply prefer a daily oral routine. The injections suit people who want once-weekly dosing, a longer established evidence record, or (in the case of Mounjaro) the dual GIP and GLP-1 mechanism that no oral medicine currently replicates. Mounjaro remains the only dual-agonist weight-loss medicine licensed in the UK.

Eligibility criteria apply to both routes. For the Wegovy tablet, the licence covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. Injectable options carry similar thresholds, detailed on the weight loss injections overview. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews the whole picture (your current health, your medicines, your history) before deciding what is appropriate. You can read more about weight loss tablets as an alternative to injections to dig further into the oral option specifically.

At nume, a GPhC-registered prescriber (a real clinician, not automated software) reads every consultation the same day it is submitted. The treatment page is the starting point if you want to check your eligibility and see which options might be right for you. The MHRA's approval of the Wegovy tablet, confirmed on the GOV.UK news pages, marks a genuine step forward for people who have been waiting for an injection-free route into this class of treatment.